Cabbacis Granted U.S. Patent for Vaporizer Pods
Vaporizer pods covered under the 724 patent that contain conventional-nicotine tobacco and hemp will provide consumers with pleasant and differentiated taste and sensory characteristics, as compared to the above vaporizer brands that contain conventional-nicotine tobacco without any hemp.
Cabbacis owns two other previously-issued
The Company's patented, reduced-nicotine, iBlend™ vaporizer pods and patented, reduced-nicotine, iBlend™ cigarettes in development are to assist vapers or smokers of conventional tobacco products to vape or smoke less or transition to less harmful tobacco or nicotine products. iBlend™ reduced-nicotine cigarettes contain approximately 95 percent less nicotine than conventional cigarette brands. The Company's products in development are patented in many of the largest tobacco markets across the globe including
About Cabbacis
Cabbacis (OTCQB: CABI) is committed to commercializing groundbreaking tobacco harm-reduction products in the global tobacco market for the world’s one billion smokers with its flagship iBlend™ reduced-nicotine cigarettes and vaporizer pods in development. These patent protected products combine reduced-nicotine tobacco with non-intoxicating hemp to assist in vaping or smoking less, transitioning to less harmful tobacco products, and/or increasing quit attempts. Both types of products in development are predominately tobacco and include hemp. In a recent clinical trial, the Company’s patented, reduced-nicotine iBlend™ cigarettes were highly rated for satisfaction on the standardized mCEQ questionnaire and significantly reduced cravings for usual brand cigarettes. The Company also plans to commercialize reduced-nicotine tobacco cigarettes and little cigars without hemp and vaporizer pods with conventional-nicotine tobacco and hemp.
The worldwide patent portfolio of
To learn more about Cabbacis, please visit cabbacis.com.
About Reduced-Nicotine Cigarettes
Reduced-nicotine cigarettes without hemp that contain about 95 percent less nicotine than conventional cigarettes have been evaluated in dozens of independent studies. Results demonstrate, as reviewed in Donny and White 2022 (Int J Drug Policy 99:103436), that subjects smoked fewer cigarettes per day, reduced their nicotine dependence and exposure, doubled their quit attempts, and/or increased their number of smoke-free days.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intend,” “likely,” “may,” “objective,” “potential,” “plan,” “predict,” “project,” “seek,” “should,” “will” and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in “Risk Factors” in our Regulation A Offering Circular filed with the
This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company’s securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of that state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250717874738/en/
Investor Relations Contact:
Managing Director
(949) 259-4987
CABI@mzgroup.us
www.mzgroup.us
Source: Cabbacis
